Formiga F, Moga I, Nolla J M, Pac M, Mitjavila F, Roig-Escofet D
Internal Medicine Service, Hospital de Bellvitge Princeps d'Espanya, L'Hospitalet de Llobregat, Barcelona, Spain.
Ann Rheum Dis. 1995 Apr;54(4):274-6. doi: 10.1136/ard.54.4.274.
To evaluate bone mineral density (BMD) in premenopausal patients with systemic lupus erythematosus (SLE).
We measured BMD by dual energy x ray absorptiometry at lumbar vertebrae L2-4 and at the right femoral neck in 74 premenopausal white patients (mean age 30.8 years) with SLE who were receiving glucocorticoid therapy, and in a control group.
The mean cumulative dose of prednisone was 32.5 (SD 28) g. The mean dose at the time of absorptiometry was 13.7 (6.9) mg. BMD was significantly reduced at the spine and at the femoral neck in SLE patients when compared with the control group: L2-4 = 0.943 (0.1) g/cm2 v 1.038 (0.1) g/cm2 (p < 0.001); femoral neck = 0.766 (0.09) g/cm2 v 0.864 (0.1) g/cm2 (p < 0.001). Nine patients (12.1%), but none of the control group, had a BMD less than the reference range.
BMD in premenopausal patients with SLE was less than that in a control group and less than the reference range of values defining the presence of osteoporosis in 12.1%. We did not find a relationship between BMD and either cumulative or baseline dose of corticosteroid therapy.
评估绝经前系统性红斑狼疮(SLE)患者的骨密度(BMD)。
我们采用双能X线吸收法测量了74例接受糖皮质激素治疗的绝经前白人SLE患者(平均年龄30.8岁)以及对照组的腰椎L2 - 4和右股骨颈的骨密度。
泼尼松的平均累积剂量为32.5(标准差28)克。吸收测定时的平均剂量为13.7(6.9)毫克。与对照组相比,SLE患者脊柱和股骨颈的骨密度显著降低:L2 - 4 = 0.943(0.1)克/平方厘米对1.038(0.1)克/平方厘米(p < 0.001);股骨颈 = 0.766(0.09)克/平方厘米对0.864(0.1)克/平方厘米(p < 0.001)。9例患者(12.1%)骨密度低于参考范围,而对照组无此情况。
绝经前SLE患者的骨密度低于对照组,且12.1%的患者骨密度低于定义骨质疏松存在的参考值范围。我们未发现骨密度与皮质类固醇治疗的累积剂量或基线剂量之间存在关联。